CN116327852A - Plaster for treating osteoarthritis and preparation method thereof - Google Patents
Plaster for treating osteoarthritis and preparation method thereof Download PDFInfo
- Publication number
- CN116327852A CN116327852A CN202310159373.2A CN202310159373A CN116327852A CN 116327852 A CN116327852 A CN 116327852A CN 202310159373 A CN202310159373 A CN 202310159373A CN 116327852 A CN116327852 A CN 116327852A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- root
- rhizoma
- plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 53
- 239000011505 plaster Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 66
- 210000000582 semen Anatomy 0.000 claims abstract description 28
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 21
- 244000080767 Areca catechu Species 0.000 claims abstract description 21
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 21
- 239000004863 Frankincense Substances 0.000 claims abstract description 21
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 241000903946 Clematidis Species 0.000 claims abstract description 10
- 241001501111 Erycibe Species 0.000 claims abstract description 8
- 241000220261 Sinapis Species 0.000 claims abstract description 8
- 241000563984 Ampelopsis Species 0.000 claims abstract description 7
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 7
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 7
- 239000010238 camphora Substances 0.000 claims abstract description 7
- 229940025250 camphora Drugs 0.000 claims abstract description 7
- 241000255791 Bombyx Species 0.000 claims abstract description 6
- 241000628997 Flos Species 0.000 claims abstract description 6
- 241000243684 Lumbricus Species 0.000 claims abstract description 6
- 241001057584 Myrrha Species 0.000 claims abstract description 6
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 6
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 6
- 241000522620 Scorpio Species 0.000 claims abstract description 6
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000009286 sanguis draxonis Substances 0.000 claims abstract description 6
- 239000009490 scorpio Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 17
- 240000007311 Commiphora myrrha Species 0.000 claims description 15
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 15
- 241000123589 Dipsacus Species 0.000 claims description 15
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 15
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 14
- 240000007551 Boswellia serrata Species 0.000 claims description 14
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 14
- 244000020518 Carthamus tinctorius Species 0.000 claims description 14
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 14
- 240000005717 Dioscorea alata Species 0.000 claims description 14
- 241001116742 Drynaria Species 0.000 claims description 14
- 241000361919 Metaphire sieboldi Species 0.000 claims description 14
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims description 14
- 241000239226 Scorpiones Species 0.000 claims description 14
- 240000004824 Trimezia steyermarkii Species 0.000 claims description 14
- 239000009136 dragon's blood Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000010517 refined sesame oil Substances 0.000 claims description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 13
- 241000255789 Bombyx mori Species 0.000 claims description 13
- 241000723346 Cinnamomum camphora Species 0.000 claims description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 13
- 229940116229 borneol Drugs 0.000 claims description 13
- 229930008380 camphor Natural products 0.000 claims description 13
- 229960000846 camphor Drugs 0.000 claims description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 13
- 241000489492 Arisaema Species 0.000 claims description 12
- 241000131329 Carabidae Species 0.000 claims description 12
- 241000212322 Levisticum officinale Species 0.000 claims description 12
- 241000972673 Phellodendron amurense Species 0.000 claims description 12
- 239000001645 levisticum officinale Substances 0.000 claims description 12
- 241000227129 Aconitum Species 0.000 claims description 11
- 235000006463 Brassica alba Nutrition 0.000 claims description 11
- 244000140786 Brassica hirta Species 0.000 claims description 11
- 235000011371 Brassica hirta Nutrition 0.000 claims description 11
- 241000501743 Gentiana macrophylla Species 0.000 claims description 11
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 11
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 11
- 241001180876 Saposhnikovia Species 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 241000219061 Rheum Species 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 235000017965 Asarum canadense Nutrition 0.000 claims description 9
- 241000218158 Clematis Species 0.000 claims description 9
- 235000000385 Costus speciosus Nutrition 0.000 claims description 9
- 239000009759 San-Chi Substances 0.000 claims description 9
- 241000606265 Valeriana jatamansi Species 0.000 claims description 9
- 235000014687 Zingiber zerumbet Nutrition 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 241001676573 Minium Species 0.000 claims description 6
- 244000170916 Paeonia officinalis Species 0.000 claims description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 239000002655 kraft paper Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 240000004980 Rheum officinale Species 0.000 claims description 4
- 235000008081 Rheum officinale Nutrition 0.000 claims description 4
- 241000758794 Asarum Species 0.000 claims description 2
- 244000292697 Polygonum aviculare Species 0.000 claims description 2
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000007480 spreading Effects 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 36
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 230000001717 pathogenic effect Effects 0.000 abstract description 11
- 230000007774 longterm Effects 0.000 abstract description 8
- 238000004904 shortening Methods 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 29
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 210000000629 knee joint Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 230000008407 joint function Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000002435 tendon Anatomy 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 7
- 210000003127 knee Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000008558 Osteophyte Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- -1 pollen typhae Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241001489980 Eupolyphaga sinensis Species 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241001369613 Stephania tetrandra Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002875 effect on osteoarthritis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/241—Lead; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a plaster for treating osteoarthritis, which is prepared from the following raw materials in parts by weight: radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, pollen Typhae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, olibanum, myrrha, carthami flos, bombyx Batryticatus, rhizoma arisaematis, radix Ampelopsis, eupolyphaga Seu Steleophaga, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, scorpio, rhizoma Ligustici Chuanxiong, sanguis Draxonis, cortex Phellodendri, notoginseng radix, caulis Erycibes, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, rhizoma Dioscoreae Bulbiferae, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, plumbum Preparatium, and refined oleum Sesami. The invention also provides a preparation method of the plaster. The invention is based on the theory of traditional Chinese medicine, and aims at the core pathogenic factors of osteoarthritis, and the invention can treat both principal and secondary aspect of the disease, thereby improving the curative effect, recovering the function and shortening the treatment period of osteoarthritis. The long-term clinical application shows that the invention has ideal curative effect and good safety.
Description
Technical Field
The invention belongs to the field of biological medicine, and relates to a traditional Chinese medicine, in particular to a plaster for treating osteoarthritis and a preparation method thereof.
Background
Osteoarthritis refers to a degenerative disease mainly manifested by joint pain caused by various factors causing articular cartilage fibrosis, chapping, ulcers and loss. The etiology is not clear, and its occurrence is related to age, obesity, inflammation, trauma, genetic factors, etc. Pathological characteristics are degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic changes, joint edge hyperosteogeny, synovial lesions, joint capsular contracture, ligament relaxation or contracture, amyotrophy and weakness, etc. Is good for middle-aged and elderly people, has high incidence rate, and is suitable for patients with osteoarthritis of more than 50% of people over 65 years old. The affected parts comprise knee joint, hip joint, ankle joint, hand joint, spine joint (cervical vertebra, lumbar vertebra), etc. Epidemiological studies have shown that osteoarthritis is the most common joint disease, affected by which 10% of men and 18% of women in the world population over 60 years old. Wherein the probability of osteoarthritis in large joints such as hip and knee joints is highest.
Osteoarthritis not only brings pain to patients and seriously affects the life quality of the patients, but also brings great economic burden to society. Osteoarthritis, while rarely leading to death, can lead to joint pain, deformity, and motor dysfunction, thereby increasing the incidence of cardiovascular events and total mortality. World health organization juxtaposes osteoarthritis with cardiovascular disease and cancer as "three killers" threatening the health of humans.
At present, the treatment of osteoarthritis mainly comprises two types of operation and non-operation, although along with the improvement of operation level and prosthesis materials, joint replacement can well solve the disease bundle disturbance for patients, and the quality of life is greatly improved. However, due to the limitation of the service life of the prosthesis, the prosthesis generally needs to be repaired after being used for about 15 to 18 years, and the difficulty and the complications of joint replacement again are obviously improved. Therefore, how to improve joint function and delay the rate of joint degeneration by non-operative therapy has become a concern. Currently, non-surgical therapies remain the primary method of treating osteoarthritis.
The medicine treatment is a main means of non-operative treatment, and comprises medicine oral administration, joint cavity administration and medicine external application. The medicine for oral administration comprises non-steroidal anti-inflammatory and analgesic drugs of Western medicine, oral administration of Chinese medicine and the like, but due to the limitation of gastrointestinal tract functions of many patients, the medicine cannot be well resistant, and the gastrointestinal tract can be damaged after long-term administration of a plurality of medicines. Meanwhile, soft tissues such as local muscles of joints are reduced in circulatory function due to joint stiffness, degeneration and the like, so that the speed of the gastrointestinal absorbed medicine entering the local joints is reduced and the concentration is lowered. The joint cavity administration comprises joint lubricating fluid, hormone and the like, but the treatment methods have limited curative effects, and even long-term injection of the hormone can further damage the joint. The adverse reaction can be avoided by local external application of the medicine, and long-term clinical practice and research show that the external application of the traditional Chinese medicine is an effective means for treating osteoarthritis. Meanwhile, various medicines in Western medicine mainly take symptom alleviation (relief of symptoms) at present, and can not radically change, delay or reverse the progress of bone joint degeneration (relief of root cause). Therefore, the development of external medicines capable of treating both symptoms and root causes is a problem which needs to be solved clinically at present.
Disclosure of Invention
Aiming at the technical problems in the prior art, the invention provides a plaster and a preparation method thereof, and the plaster for treating osteoarthritis and the preparation method thereof aim to solve the technical problem that medicines in the prior art have poor curative effect on osteoarthritis.
The invention provides a plaster for treating osteoarthritis; the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
10-20 parts of raw radix aconiti, 10-20 parts of raw kusnezoff monkshood root, 10-20 parts of semen pini koraiensis, 10-20 parts of white mustard seed, 10-20 parts of pollen typhae, 10-20 parts of raw rheum officinale, 10-20 parts of large-leaf gentian root, 10-20 parts of frankincense, 10-20 parts of myrrh, 10-20 parts of safflower, 10-20 parts of stiff silkworm, 10-20 parts of arisaema tuber, 10-20 parts of Japanese ampelopsis root, 10-20 parts of ground beetle, 10-20 parts of earthworm, 10-20 parts of asarum, 10-20 parts of dipsacus root, 10-20 parts of giant knotweed rhizome, 10-20 parts of scorpion, 10-20 parts of szechuan lovage rhizome, 10-20 parts of dragon's blood resin, 10-20 parts of amur corktree bark, 10-20 parts of pseudo-ginseng, 10-20 parts of common flowery knotweed herb, 10-20 parts of camphor, 5-15 parts of borneol, 10-20 parts of catechu, 10-20 parts of white drug seed, 10-20 parts of airpotato yam rhizome, 10-20 parts of radix sileris, 10-20 parts of divaricate saposhnikovia root, 10-20 parts of radix angelicae, 10-20 parts of drynariae, 10-20 parts of drynaria rhizome, 10-20 parts of radix clematidis, 10-20 parts of common aucklandia root, 10-20 parts of common peony root, 10-100 parts of 500 parts of common peony root, 10-500 parts of common peony root, 10-500 parts of common-fruit.
Further, the plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
10 parts of raw radix aconiti, 10 parts of raw kusnezoff monkshood root, 10 parts of semen pini koraiensis, 10 parts of white mustard seed, 10 parts of pollen typhae, 10 parts of raw rhubarb, 10 parts of large-leaf gentian root, 10 parts of frankincense, 10 parts of myrrh, 10 parts of safflower, 10 parts of stiff silkworm, 10 parts of arisaema tuber, 10 parts of Japanese ampelopsis root, 10 parts of ground beetle, 10 parts of earthworm, 10 parts of manchurian wildginger, 10 parts of dipsacus root, 10 parts of giant knotweed rhizome, 10 parts of scorpion, 10 parts of szechuan lovage rhizome, 10 parts of dragon's blood resin, 10 parts of amur corktree bark, 10 parts of sanchi, 10 parts of common public vine, 10 parts of camphor, 5 parts of borneol, 10 parts of catechu, 10 parts of white drug seed, 10 parts of airpotato yam, 10 parts of notopterygium root, 10 parts of divaricate saposhnikovia root, 10 parts of drynaria rhizome, 10 parts of radix clematis, 100 parts of guangdaline, 500 parts of refined sesame oil.
Further, the plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
15 parts of raw radix aconiti, 15 parts of raw kusnezoff monkshood root, 15 parts of semen pini koraiensis, 15 parts of white mustard seed, 15 parts of pollen typhae, 15 parts of raw rhubarb, 15 parts of large-leaf gentian root, 15 parts of frankincense, 15 parts of myrrh, 15 parts of safflower, 15 parts of stiff silkworm, 15 parts of arisaema tuber, 15 parts of Japanese ampelopsis root, 15 parts of ground beetle, 15 parts of earthworm, 15 parts of manchurian wildginger, 15 parts of dipsacus root, 15 parts of giant knotweed rhizome, 15 parts of scorpion, 15 parts of szechuan lovage rhizome, 15 parts of dragon's blood resin, 15 parts of amur corktree bark, 15 parts of sanchi, 15 parts of common public vine, 15 parts of camphor, 10 parts of borneol, 15 parts of catechu, 15 parts of white drug seed, 15 parts of airpotato yam, 15 parts of notopterygium root, 15 parts of divaricate saposhnikovia root, 15 parts of drynaria rhizome, 15 parts of radix clematis, 150 parts of minium, and 600 parts of refined sesame oil.
Further, the plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
20 parts of raw radix aconiti, 20 parts of raw kusnezoff monkshood root, 20 parts of semen pini koraiensis, 20 parts of white mustard seed, 20 parts of pollen typhae, 20 parts of raw rhubarb, 20 parts of large-leaf gentian root, 20 parts of frankincense, 20 parts of myrrh, 20 parts of safflower, 20 parts of stiff silkworm, 20 parts of arisaema tuber, 20 parts of Japanese ampelopsis root, 20 parts of ground beetle, 20 parts of earthworm, 20 parts of manchurian wildginger, 20 parts of dipsacus root, 20 parts of giant knotweed rhizome, 20 parts of scorpion, 20 parts of szechuan lovage rhizome, 20 parts of dragon's blood resin, 20 parts of amur corktree bark, 20 parts of sanchi, 20 parts of common public vine, 20 parts of camphor, 15 parts of borneol, 20 parts of catechu, 20 parts of white drug seed, 20 parts of airpotato yam, 20 parts of notopterygium root, 20 parts of divaricate saposhnikovia root, 20 parts of drynaria rhizome, 20 parts of radix clematis, 200 parts of minium, 700 parts of refined sesame oil.
Further, the plaster for treating osteoarthritis also contains pharmaceutically acceptable pharmaceutical excipients.
The invention also provides a preparation method of the plaster for treating osteoarthritis, which comprises the following steps:
1) Weighing the raw materials in parts by weight for later use;
2) Pulverizing pollen Typhae, olibanum, myrrha, radix Ampelopsis, eupolyphaga Seu Steleophaga, scorpio, sanguis Draxonis, notoginseng radix, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, and rhizoma Dioscoreae Bulbiferae respectively, grinding into fine powder, sieving, mixing, and making into medicinal powder;
3) Mixing radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, carthami flos, bombyx Batryticatus, rhizoma arisaematis, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, rhizoma Ligustici Chuanxiong, cortex Phellodendri, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, soaking in refined sesame oil for 7-10 days, pouring into a pot, frying with slow fire to golden yellow, taking out residues, retaining medicinal oil, adding Plumbum Preparatium, stirring, decocting until white smoke is generated, dripping water to form beads, finally turning off fire, air drying to warm, adding the powder obtained in step 2), and decocting to obtain paste;
4) And (3) carrying out hot melting on the ointment in the step (3), and uniformly spreading the ointment on the cut kraft paper, wherein each patch is 30-35g.
Specifically, in the step 1), 13 raw medicinal materials such as pollen typhae, frankincense, myrrh, radix ampelopsis, ground beetle, scorpion, dragon's blood, pseudo-ginseng, camphor, borneol, catechu, airpotato yam and the like are processed by an ultrafine grinding technology and pass through a No. 9 screen to obtain ultrafine powder (more than 200 meshes) for standby;
osteoarthritis belongs to the category of Chinese medicinal arthralgia, and is one of the current clinical chronic muscle and bone diseases. The etiology of the disease is that three pathogenic factors of wind, cold and dampness block the channels and collaterals; additionally, the deficiency of liver and kidney, malnutrition of tendons and bones, weak tendons and bones, pathogenic factors attacking bone and vein, stagnation of qi and blood, and stagnation of blood stasis and pathogenic factors with each other; so that qi and blood are not smooth, and blood is not nourished, so that movement is limited; pain in the joints due to obstructed venation. Kidney deficiency and blood stasis are the main pathogenic factors of the disease, liver and kidney deficiency are the principal and phlegm and blood stasis are the principal and secondary aspects of the disease. Therefore, the traditional Chinese medicine considers that the treatment of the disease is key to tonifying liver and kidney, warming channel and dredging collaterals, activating blood and removing blood stasis, and relieving swelling and pain.
A plurality of modern clinical researches show that the traditional Chinese medicine therapies such as tonifying liver and kidney, promoting blood circulation to remove blood stasis, warming channel and dredging collaterals can effectively relieve osteoarthritis symptoms, relieve pain and improve joint functions. However, monotherapy has limited effectiveness. Because osteoarthritis is a lesion of a part of a joint, the human body is organically unified, and from the perspective of the traditional Chinese medicine, osteoarthritis involves liver, kidney, spleen and stomach, bone, tendons, muscles, blood vessels, skin, etc., rather than a single tissue or system. Meanwhile, from the theory of traditional Chinese medicine, the organizations have interdependence. Therefore, after comprehensively and comprehensively analyzing various factors of osteoarthritis, the prescription thought of the external plaster is provided by combining the traditional Chinese medicine theory, namely, the whole treatment and the principal and subordinate symptoms are considered.
In view of this, we propose the therapeutic method of invigorating liver and kidney, warming channel and dredging collaterals, promoting blood circulation and removing blood stasis, dispelling wind and removing dampness, detumescence and relieving pain, the method takes into account the pathogenic factors of osteoarthritis, takes dipsacus root, rhizoma drynariae, eupolyphaga and the like into consideration to tonify liver and kidney, strengthen tendons and bones, pollen typhae, raw rheum officinale, olibanum, myrrh, safflower, earthworm, ligusticum wallichii, pseudo-ginseng and the like to promote blood circulation and remove blood stasis, detumescence and relieving pain, and radix aconiti kusnezoffii are used for warming channel and dispelling cold, dredging collaterals and relieving pain, and treating both principal and secondary aspect of disease. In addition, wind-dispelling medicines are added into the formula. The traditional Chinese medicine theory and modern research show that the wind-dispelling medicine can quickly dredge channels and collaterals, can effectively accelerate blood circulation, improve local soft tissue environment conditions of joints, and help other medicines to quickly enter local soft tissues so as to better exert curative effects.
Considering the problems of resolving heat by stasis and resolving heat by long time, the invention adopts phellodendron bark to clear heat and remove dampness, and Japanese ampelopsis and catechu to clear heat and remove toxicity. Thereby better and comprehensively playing the curative effect, preventing the drug bias, further preventing side effects and improving the safety.
In the external plaster preparation, the medicinal materials of pollen typhae, raw rhubarb, frankincense, myrrh, safflower, earthworm, szechuan lovage rhizome, pseudo-ginseng and dragon's blood have the effects of promoting blood circulation by removing blood stasis, dredging collaterals and relieving pain, and modern pharmacological researches also show that the blood circulation-promoting and blood stasis-removing medicine can effectively promote blood circulation and improve tissue blood supply. The medicinal materials of dipsacus root, drynaria rhizome and eupolyphaga sinensis Walker have the effects of tonifying liver and kidney, and strengthening tendons and bones. Modern researches have shown that dipsacus root, drynaria rhizome and eupolyphaga sinensis are effective in promoting fracture healing and improving the strength of trabecula. Radix Aconiti, radix Aconiti Kusnezoffii, rhizoma Polygoni Cuspidati, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, radix Clematidis, radix Gentianae Marcrophyllae, semen Pisi Sativi, and herba asari by dispelling pathogenic wind, dispelling cold, removing dampness and relieving pain; the medicines of stiff silkworm, arisaema tuber and scorpion have the effects of dispelling wind, resolving masses, dredging collaterals and relieving pain; the Japanese ampelopsis and the catechu have the effects of clearing heat and detoxicating, resolving hard mass and promoting tissue regeneration; the white drug powder has the effects of clearing heat and detoxicating, cooling blood and stopping bleeding, and removing stasis and detumescence; the airpotato yam has the functions of detoxication, detumescence, resolving phlegm, resolving masses, cooling blood and stopping bleeding; semen Sinapis Albae has effects of eliminating phlegm, activating qi-flowing, resolving hard mass, dredging collaterals and relieving pain; cortex Phellodendri has effects of clearing heat and eliminating dampness; camphor and borneol, which have the functions of dredging orifices, reducing swelling and relieving pain.
Kidney governs bone and liver governs tendons, and liver and kidney deficiency is a major factor (endogenous factor) in the onset of osteoarthritis. The plaster takes three medicines of dipsacus root, drynaria rhizome and eupolyphaga sinensis Walker as monarch drugs, and aims at the most critical internal factors of the pathogenesis of osteoarthritis, and has the effects of tonifying liver and kidney and strengthening tendons and bones. Radix Aconiti, radix Aconiti Kusnezoffii, rhizoma Polygoni Cuspidati, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, radix Clematidis, radix Gentianae Marcrophyllae, semen Pittospori Glabrati, herba asari, and semen Pittoi Glabrati by warming channels for dispelling cold, dispelling pathogenic wind and removing dampness; the stiff silkworm, the rhizoma arisaematis and the scorpion are used for dispelling wind and resolving masses; these drugs are ministerial drugs, and they mainly aim at external factors (exogenous factors) of the onset of osteoarthritis such as wind, cold, dampness, etc. Meanwhile, blood stasis is also an important pathogenic factor in the pathogenesis of osteoarthritis, so that blood-activating and stasis-resolving herbs such as pollen typhae, raw rheum officinale, frankincense, myrrh, safflower, earthworm, ligusticum wallichii, pseudo-ginseng, dragon's blood, stephania root, airpotato yam and the like are taken as adjuvant drugs. Radix Ampelopsis, catechu, semen Sinapis Albae, cortex Phellodendri, camphora, borneolum Syntheticum, etc. as guiding drugs for resolving phlegm, resolving hard mass, clearing heat and detoxicating, and dredging Li Guanqiao (shown in figure 1).
The external plaster of the invention has the functions of warming channels and expelling cold, clearing heat and detoxicating, clearing heat and cooling blood, and combining cold and heat with cold and warm. Meanwhile, the prescription has the medicines for tonifying the liver and kidney, activating blood circulation to dissipate blood stasis, relieving swelling and pain, dispelling wind, removing dampness and dredging collaterals, and can treat both principal and secondary aspect of disease. Thereby obviously enlarging the treatment range of the external plaster, enhancing the curative effect and obviously reducing the side effect.
The invention has the characteristics and benefits that:
the plaster has the advantages of reference to the classical method of the traditional Chinese medicine external preparation, controllable quality, quick response, definite curative effect, small irritation to human skin, suitability for long-term administration and reliable long-term curative effect.
The preparation disclosed by the invention has the effects of dispelling wind, dredging collaterals, dehumidifying, detumescence, promoting blood circulation, removing blood stasis, strengthening tendons and bones, and can effectively promote local blood circulation of joints and relieve joint swelling and pain.
According to the traditional Chinese medicine prescription thought compatibility, the traditional Chinese medicine composition can effectively relieve symptoms such as pain and the like aiming at core pathogenic factors and main pathogenesis of osteoarthritis, and promote function improvement.
The long-term clinical application of the invention shows that the invention has good curative effect, can treat both principal and secondary aspect of disease, relieves the pain for a plurality of patients, and is popular with the patients.
Compared with the prior art, the invention has obvious technical progress. The invention is based on the theory of traditional Chinese medicine, and aims at the core pathogenic factors of chronic bone and muscle diseases (osteoarthritis) under the whole-view guidance of the traditional Chinese medicine, and the traditional Chinese medicine can treat both principal and secondary aspect of disease, thereby improving the curative effect, recovering the function and shortening the treatment period of osteoarthritis. Long-term clinical application shows that the medicine has ideal curative effect and good safety.
Drawings
Fig. 1 is a diagram showing the relationship between monarch, minister, assistant and guide of a plaster for treating osteoarthritis.
Detailed Description
The invention is further described in detail in order to make the objects, technical solutions and advantageous effects of the invention more clear. It should be understood that the detailed description and specific examples, while indicating the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
A plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
10 parts of raw radix aconiti, 10 parts of raw kusnezoff monkshood root, 10 parts of semen pini koraiensis, 10 parts of white mustard seed, 10 parts of pollen typhae, 10 parts of raw rhubarb, 10 parts of large-leaf gentian root, 10 parts of frankincense, 10 parts of myrrh, 10 parts of safflower, 10 parts of stiff silkworm, 10 parts of arisaema tuber, 10 parts of Japanese ampelopsis root, 10 parts of ground beetle, 10 parts of earthworm, 10 parts of manchurian wildginger, 10 parts of dipsacus root, 10 parts of giant knotweed rhizome, 10 parts of scorpion, 10 parts of szechuan lovage rhizome, 10 parts of dragon's blood resin, 10 parts of amur corktree bark, 10 parts of sanchi, 10 parts of common public vine, 10 parts of camphor, 5 parts of borneol, 10 parts of catechu, 10 parts of white drug seed, 10 parts of airpotato yam, 10 parts of notopterygium root, 10 parts of divaricate saposhnikovia root, 10 parts of drynaria rhizome, 10 parts of radix clematis, 100 parts of guangdaline, 500 parts of refined sesame oil.
The preparation method of the external plaster of the embodiment comprises the following steps:
1) Weighing the medicinal materials according to the prescription proportion of the embodiment 1 for standby;
2) Pulverizing 13 medicinal materials including pollen Typhae, olibanum, myrrha, radix Ampelopsis, eupolyphaga Seu Steleophaga, scorpio, sanguis Draxonis, notoginseng radix, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, and rhizoma Dioscoreae Bulbiferae respectively, grinding into fine powder, sieving, mixing, and making into medicinal powder;
3) Mixing radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, carthami flos, bombyx Batryticatus, rhizoma arisaematis, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, rhizoma Ligustici Chuanxiong, cortex Phellodendri, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, soaking in refined sesame oil for 7-10 days, pouring into a pot, frying with slow fire to golden yellow, taking out residues, retaining medicinal oil, adding Plumbum Preparatium, stirring, decocting until white smoke is generated, dripping water to form beads, finally turning off fire, air drying to warm, adding the powder obtained in step 2), and decocting to obtain paste.
4) The ointment is melted and evenly spread on the cut kraft paper, and 30g of ointment is pasted each time.
Example 2
A plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
20 parts of raw radix aconiti, 20 parts of raw kusnezoff monkshood root, 20 parts of semen pini koraiensis, 20 parts of white mustard seed, 20 parts of pollen typhae, 20 parts of raw rhubarb, 20 parts of large-leaf gentian root, 20 parts of frankincense, 20 parts of myrrh, 20 parts of safflower, 20 parts of stiff silkworm, 20 parts of arisaema tuber, 20 parts of Japanese ampelopsis root, 20 parts of ground beetle, 20 parts of earthworm, 20 parts of manchurian wildginger, 20 parts of dipsacus root, 20 parts of giant knotweed rhizome, 20 parts of scorpion, 20 parts of szechuan lovage rhizome, 20 parts of dragon's blood resin, 20 parts of amur corktree bark, 20 parts of sanchi, 20 parts of common public vine, 20 parts of camphor, 15 parts of borneol, 20 parts of catechu, 20 parts of white drug seed, 20 parts of airpotato yam, 20 parts of notopterygium root, 20 parts of divaricate saposhnikovia root, 20 parts of drynaria rhizome, 20 parts of radix clematis, 200 parts of minium, 700 parts of refined sesame oil.
The preparation method of the external plaster of the embodiment comprises the following steps:
1) Weighing the medicinal materials according to the prescription proportion of the embodiment 2 for standby;
2) Pulverizing 13 medicinal materials including pollen Typhae, olibanum, myrrha, radix Ampelopsis, eupolyphaga Seu Steleophaga, scorpio, sanguis Draxonis, notoginseng radix, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, and rhizoma Dioscoreae Bulbiferae respectively, grinding into fine powder, sieving, mixing, and making into medicinal powder;
3) Mixing radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, carthami flos, bombyx Batryticatus, rhizoma arisaematis, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, rhizoma Ligustici Chuanxiong, cortex Phellodendri, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, soaking in refined sesame oil for 7-10 days, pouring into a pot, frying with slow fire to golden yellow, taking out residues, retaining medicinal oil, adding Plumbum Preparatium, stirring, decocting until white smoke is generated, dripping water to form beads, finally turning off fire, air drying to warm, adding the powder obtained in step 2), and decocting to obtain paste.
4) The ointment is melted and evenly spread on the cut kraft paper, and each patch is 35g.
Example 3
A plaster for treating osteoarthritis is prepared from the following raw materials in parts by weight:
15 parts of raw radix aconiti, 15 parts of raw kusnezoff monkshood root, 15 parts of semen pini koraiensis, 15 parts of white mustard seed, 15 parts of pollen typhae, 15 parts of raw rhubarb, 15 parts of large-leaf gentian root, 15 parts of frankincense, 15 parts of myrrh, 15 parts of safflower, 15 parts of stiff silkworm, 15 parts of arisaema tuber, 15 parts of Japanese ampelopsis root, 15 parts of ground beetle, 15 parts of earthworm, 15 parts of manchurian wildginger, 15 parts of dipsacus root, 15 parts of giant knotweed rhizome, 15 parts of scorpion, 15 parts of szechuan lovage rhizome, 15 parts of dragon's blood resin, 15 parts of amur corktree bark, 15 parts of sanchi, 15 parts of common public vine, 15 parts of camphor, 10 parts of borneol, 15 parts of catechu, 15 parts of white drug seed, 15 parts of airpotato yam, 15 parts of notopterygium root, 15 parts of divaricate saposhnikovia root, 15 parts of drynaria rhizome, 15 parts of radix clematis, 150 parts of minium, and 600 parts of refined sesame oil.
The preparation method of the external plaster of the embodiment comprises the following steps:
1) Weighing the medicinal materials according to the prescription proportion of the embodiment 3 for standby;
2) Pulverizing 13 medicinal materials including pollen Typhae, olibanum, myrrha, radix Ampelopsis, eupolyphaga Seu Steleophaga, scorpio, sanguis Draxonis, notoginseng radix, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, and rhizoma Dioscoreae Bulbiferae respectively, grinding into fine powder, sieving, mixing, and making into medicinal powder;
3) Mixing radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, carthami flos, bombyx Batryticatus, rhizoma arisaematis, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, rhizoma Ligustici Chuanxiong, cortex Phellodendri, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, soaking in refined sesame oil for 7-10 days, pouring into a pot, frying with slow fire to golden yellow, taking out residues, retaining medicinal oil, adding Plumbum Preparatium, stirring, decocting until white smoke is generated, dripping water to form beads, finally turning off fire, air drying to warm, adding the powder obtained in step 2), and decocting to obtain paste.
4) The ointment is melted and evenly spread on the cut kraft paper, and 30g of ointment is pasted each time.
The plaster of the invention comprises the following steps: cleaning the affected part with warm water, baking with soft fire, and applying to the affected part for three days, wherein 2 patches are improved. The 10 plasters are used as a treatment course, the recovery can be realized after 2 to 3 treatment courses, and the recovery can be realized after 3 to 5 treatment courses for patients with particularly serious symptoms.
In order to verify the treatment effect of the external traditional Chinese medicine preparation for treating osteoarthritis, a single-center random single-blind parallel control research method is adopted.
1. 120 subjects were divided into two groups (60 in each of the treatment group and the control group) using a completely randomized method, and all of them were subjected to total treatment
The selected patients are numbered according to the order of visit, and are grouped in random digital mode by adopting SAS statistical analysis software. The random assignment scheme is hidden (enclosed in a sealed, opaque envelope coded in sequence) to assign treatment and registered.
2. Case selection
2.1 Western diagnostic criteria: reference is made to the knee osteoarthritis diagnostic classification revised in 1995 of the American society of rheumatology.
2.1.1 clinical:
(1) knee pain occurs most of the time for nearly 1 month;
(2) bone fricatives are present when the joint is moving;
(3) morning stiffness is less than or equal to 30 minutes;
(4) age >38 years old;
(5) knee joints have bony enlargement.
Can be diagnosed by satisfying (1) + (2) + (3) + (4), or (1) + (2) + (5), or (1) + (4) or (5)
2.1.2 clinical+laboratory+radiology:
(1) knee pain occurs most of the time for nearly 1 month;
(2) x-ray film shows bone praise formation;
(3) joint fluid examination was consistent with osteoarthritis (clear, viscous, WBC <2 x 109/L);
(4) age not less than 40 years old (person unable to check joint fluid);
(5) morning stiffness is less than or equal to 30 minutes;
(6) bone fricatives are present when the joint is moving.
The knee osteoarthritis can be diagnosed by satisfying (1) + (2) or (1) ten (3) + (5) + (6) or (1) + (4) + (5) + (6).
2.1.3 dialectical criteria of TCM: the reference to the "therapeutic effect standard for diagnosing diseases in traditional Chinese medicine-.
2.1.3.1 main symptoms: (1) knee joint pain; (2) shin soft knee soreness.
2.1.3.2 times of symptoms: (1) local tenderness; (2) swelling of the joints; (3) difficulty in walking; (4) skin muscular atrophy; (5) a joint movement disorder; (6) pale or reddish tongue; (7) thin or thin white coating; (8) slippery or wiry pulse.
2.1.4X-ray grading criteria for knee osteoarthritis: the Kellgren & Lawrence grading standard, which refers to X-ray changes, is classified as 5.
Level 0: is normal
Stage I: the joint space is suspected to be narrowed, and osteophytes may exist;
stage II: obvious osteophytes exist, and the joint gap is suspected to be narrowed;
III grade: moderate osteophytes, more definite narrowing of joint gaps and hardening change;
grade IV: a great deal of osteophytes, obviously narrowed joint gaps and obviously deformed severe sclerotic lesion mechanisms.
2.2 test case Standard
2.2.1 case inclusion criteria
(1) The clinical manifestation of the KOA meets the Western diagnosis standard of the KOA, and the X-ray manifestation is between I and III;
(2) meets the dialectical standard of the stasis of the tendons and the vessels of the traditional Chinese medicine;
(3) age above 40 years old and below 60 years old;
(4) voluntarily as a tested object, signs an informed consent form, and can accept the tested pharmaceutical dosage form to ensure the completion of the treatment course.
2.2.2 case exclusion criteria
(1) The patients do not meet the diagnosis standard of Western medicine diseases and Chinese medicine differentiation;
(2) age <40 years or >60 years old;
(3) gestation and lactation of women;
(4) the complications affect the joint, such as psoriasis, syphilis neuropathy, metabolic bone diseases, acute trauma, etc.;
(5) other drugs for treating this disease are used in the near two weeks;
(6) advanced deformity, disability and disability;
(7) primary diseases and mental patients with cardiovascular, liver, kidney, hematopoietic system, etc.;
(8) critical illness is difficult to make exact judgment on the curative effect or safety of the medicine.
2.2.3 cases of rejection and abscission
(1) The patients cannot follow the test method on time as a withdrawal or drop test.
(2) The subject indicated termination of the test or severe adverse reactions.
(3) An accident occurs during the treatment process and the person who can not adhere to the treatment can not stay.
(4) Cases cannot be visited on schedule (2 days before and after the scheduled period).
(5) The rejection rate and the shedding rate are less than 20 percent.
3. Therapeutic method
3.1 treatment group
The external preparation of example 1 of the present invention produced a plaster.
The method comprises the following steps: cleaning skin, applying the plaster spread on kraft paper to affected part, and bandaging with a bandage. The plaster is taken down after being attached for 8-10 hours for 1 time per day.
Treatment course: the administration was continued for 2 weeks.
3.2 control group
Gutong paste (trade name: tianhe, guilin Huarun Tianhe pharmaceutical Co., ltd.)
The method comprises the following steps: cleaning skin, and applying the bone paste to affected part. The plaster is taken down after being attached for 8-10 hours for 1 time per day.
Treatment course: the same treatment group.
4. Observation index
4.1 safety Observation
4.1.1 demographics: including age (range), gender, race, height, weight, health history, medication history, allergy history, disease history, etc.
4.1.2 general physical examination: such as respiration, heart rate, blood pressure, pulse, etc.
4.1.3 adverse reaction index: the method is formulated by referring to the Chinese medicine research guidelines (pharmacy, pharmacology and toxicology), and is used for observing the irritation of the skin around skin lesions, and observing whether the skin is pigmented, bleeding spots, rough skin or thin skin and the like at the application part.
4.1.4 therapeutic efficacy index
4.1.4.1 pain degree assessment: visual analog grading (VAS score).
4.1.4.2lysholm knee function score: the method is carried out in a questionnaire mode. The Lysholm knee scoring scale includes 8 aspects of lameness, support, cross-locking, instability, pain, swelling, going up and down stairs, squatting, each with a respective score for a total of 100 points. Higher scores indicate better knee function. The items and scores evaluated are detailed in the following table.
4.2 observation time:
before treatment, after 1 week and 3 weeks
5. Follow-up visit
1 visit 1 time each 1 month and 3 months after the treatment is finished, and the follow-up is carried out in a review or telephone mode. And (5) observing the cure rate and recurrence rate of the obvious cases.
6. Clinical evaluation: and (5) comprehensive curative effect assessment. The scoring standard is formulated by referring to the clinical study guidelines for treating osteoarthritis of the novel traditional Chinese medicine, and the clinical curative effect is judged and is divided into four stages of clinical control, obvious effect, effective and ineffective. The method comprises the following steps:
(1) clinical control: pain symptoms disappear and the joint moves normally.
(2) The effect is shown: pain symptoms basically disappear, and the joint functions basically normal, and can participate in normal activities and works.
(3) The method is effective: pain is substantially eliminated, joint movement is mildly restricted, and the ability to participate in activities or work is improved.
(4) Invalid, and not reaching the valid standard.
The enrolled subjects were randomized into treatment groups (60 cases) and control groups (60 cases), and the sex profiles of the two groups of patients are detailed in table 1.
TABLE 1 sex profiles of two groups of patients
| Group of | N | Man's body | Female |
| Control group | 60 | 32 | 40 |
| Treatment group | 60 | 38 | 34 |
The chi-square test shows that the P value is larger than 0.05, and the two groups of sexes are not obviously different.
The age and course of the two groups of patients are shown in Table 2.
Table 2 age and disease course comparison of treatment and control groups
Through statistical analysis processing, the non-parameter (M-W) test of two independent samples, the comparison P value between each index group is larger than 0.05, and the age and disease course of the two groups of samples are not obviously different.
The pre-treatment pain (VAS) profile for the two groups of patients is shown in Table 3.
TABLE 3 comparison of pain conditions (VAS) before treatment for the treated and control groups
| Group of | N | VAS |
| Treatment group | 60 | 7.35±1.02 |
| Control group | 60 | 7.87±0.96 |
Statistical analysis and comparison between groups uses x 2 The comparison P-value between the two groups was greater than 0.05, suggesting that there was no significant difference in pain levels before treatment for the two groups of patients.
The pain (VAS) profile of the two groups of patients after 1 week of treatment is shown in Table 4.
TABLE 4 pain conditions (VAS) comparison after 1 week of treatment of the treatment group and the control group
| Group of | N | VAS |
| Treatment group | 60 | 4.39±0.83 |
| Control group | 60 | 5.35±1.04 |
Statistical analysis and comparison between groups uses x 2 The comparison P value between the two groups was less than 0.05, suggesting a significant difference in pain levels after 1 week of treatment for both groups of patients, with the treatment group being superior to the control group.
The pain (VAS) profile of the two groups of patients after 3 weeks of treatment is shown in Table 5.
TABLE 5 pain conditions (VAS) comparison after 3 weeks of treatment of the treatment group and the control group
| Group of | N | VAS |
| Treatment group | 60 | 1.79±1.02 |
| Control group | 60 | 2.67±0.92 |
Statistical analysis and comparison between groups uses x 2 The comparison P value between the two groups is smaller than 0.05, which indicates that the pain degree of the two groups of patients treated for 3 weeks is obviously reduced, and the treatment group is obviously better than the control group.
The functional status of the knee joint before treatment for the two groups of patients is shown in Table 6.
Table 6, comparison of Lysholm knee scores prior to treatment in treatment and control groups
| Group of | N | Lysholm score |
| Treatment group | 60 | 56.74±12.29 |
| Control group | 60 | 54.43±12.35 |
Statistical analysis and comparison between groups uses x 2 The comparison P value between the two groups is larger than 0.05, which indicates that the knee joint functions of the two groups of patients are not significantly different before treatment.
The knee joint function of the two groups of patients after 1 week of treatment is shown in Table 7.
Table 7, lysholm knee score comparison after 1 week of treatment with treatment and control groups
| Group of | N | Lysholm score |
| Treatment group | 60 | 68.85±9.28 |
| Control group | 60 | 60.67±10.09 |
After treatment for 1 week, both groups of patients had significantly improved knee joint function over that before treatment. Comparison between groups uses x 2 The comparison P value between the two groups is smaller than 0.05, which indicates that the knee joint functions of the two groups of patients are obviously different after 1 week of treatment, and the treatment group is better than the control group.
The knee joint function of the two groups of patients after 3 weeks of treatment is shown in Table 8.
Table 8, lysholm knee score comparison after 3 weeks of treatment with treatment and control groups
| Group of | N | Lysholm score |
| Treatment group | 60 | 85.28±10.45 |
| Control group | 60 | 78.63±9.54 |
After treatment for 3 weeks, the knee joint function of both groups of patients continued to improve. Comparison between groups uses x 2 The comparison P value between the two groups is smaller than 0.05, which indicates that the knee joint functions of the two groups of patients are obviously different after 3 weeks of treatment, and the treatment group is better than the control group.
The comprehensive efficacy assessment after 3 weeks of treatment for both groups of patients is detailed in Table 9.
Table 9, comprehensive efficacy comparison of the two groups of patients after 3 weeks of treatment.
| Group of | N | Clinical control | Has obvious effect | Effective and effective | Invalidation of | Effective rate (%) |
| Treatment group | 60 | 34 | 15 | 4 | 7 | 88.33 |
| Control group | 60 | 29 | 13 | 6 | 12 | 80 |
After 3 weeks of treatment, the effective rate of the treatment group is 88.83%, and the effective rate of the control group is 80%. After 3 weeks of treatment, the treatment group had significantly higher effective rate than the control group and had statistical significance (P value less than 0.05).
Therefore, the research shows that the external plaster preparation has good clinical curative effect and obvious effect compared with the existing external plaster in clinic.
Further clinical observation and research show that the external plaster preparation for treating osteoarthritis has the advantages of obvious curative effect, shortened treatment course, low incidence of side effect and good safety compared with the existing external preparation in clinic.
The above embodiments are merely preferred embodiments of the present invention, and are not intended to limit the present invention, but any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the scope of the present invention.
Claims (6)
1. The plaster for treating osteoarthritis is characterized by being prepared from the following raw materials in parts by weight:
10-20 parts of raw radix aconiti, 10-20 parts of raw kusnezoff monkshood root, 10-20 parts of semen pini koraiensis, 10-20 parts of white mustard seed, 10-20 parts of pollen typhae, 10-20 parts of raw rheum officinale, 10-20 parts of large-leaf gentian root, 10-20 parts of frankincense, 10-20 parts of myrrh, 10-20 parts of safflower, 10-20 parts of stiff silkworm, 10-20 parts of arisaema tuber, 10-20 parts of Japanese ampelopsis root, 10-20 parts of ground beetle, 10-20 parts of earthworm, 10-20 parts of asarum, 10-20 parts of dipsacus root, 10-20 parts of giant knotweed rhizome, 10-20 parts of scorpion, 10-20 parts of szechuan lovage rhizome, 10-20 parts of dragon's blood resin, 10-20 parts of amur corktree bark, 10-20 parts of pseudo-ginseng, 10-20 parts of common flowery knotweed herb, 10-20 parts of camphor, 5-15 parts of borneol, 10-20 parts of catechu, 10-20 parts of white drug seed, 10-20 parts of airpotato yam rhizome, 10-20 parts of radix sileris, 10-20 parts of divaricate saposhnikovia root, 10-20 parts of radix angelicae, 10-20 parts of drynariae, 10-20 parts of drynaria rhizome, 10-20 parts of radix clematidis, 10-20 parts of common aucklandia root, 10-20 parts of common peony root, 10-100 parts of 500 parts of common peony root, 10-500 parts of common peony root, 10-500 parts of common-fruit.
2. The plaster for treating osteoarthritis as claimed in claim 1, wherein the plaster is prepared from the following raw materials in parts by weight:
15 parts of raw radix aconiti, 15 parts of raw kusnezoff monkshood root, 15 parts of semen pini koraiensis, 15 parts of white mustard seed, 15 parts of pollen typhae, 15 parts of raw rhubarb, 15 parts of large-leaf gentian root, 15 parts of frankincense, 15 parts of myrrh, 15 parts of safflower, 15 parts of stiff silkworm, 15 parts of arisaema tuber, 15 parts of Japanese ampelopsis root, 15 parts of ground beetle, 15 parts of earthworm, 15 parts of manchurian wildginger, 15 parts of dipsacus root, 15 parts of giant knotweed rhizome, 15 parts of scorpion, 15 parts of szechuan lovage rhizome, 15 parts of dragon's blood resin, 15 parts of amur corktree bark, 15 parts of sanchi, 15 parts of common public vine, 15 parts of camphor, 10 parts of borneol, 15 parts of catechu, 15 parts of white drug seed, 15 parts of airpotato yam, 15 parts of notopterygium root, 15 parts of divaricate saposhnikovia root, 15 parts of drynaria rhizome, 15 parts of radix clematis, 150 parts of minium, and 600 parts of refined sesame oil.
3. The plaster for treating osteoarthritis as claimed in claim 1, wherein the plaster is prepared from the following raw materials in parts by weight:
10 parts of raw radix aconiti, 10 parts of raw kusnezoff monkshood root, 10 parts of semen pini koraiensis, 10 parts of white mustard seed, 10 parts of pollen typhae, 10 parts of raw rhubarb, 10 parts of large-leaf gentian root, 10 parts of frankincense, 10 parts of myrrh, 10 parts of safflower, 10 parts of stiff silkworm, 10 parts of arisaema tuber, 10 parts of Japanese ampelopsis root, 10 parts of ground beetle, 10 parts of earthworm, 10 parts of manchurian wildginger, 10 parts of dipsacus root, 10 parts of giant knotweed rhizome, 10 parts of scorpion, 10 parts of szechuan lovage rhizome, 10 parts of dragon's blood resin, 10 parts of amur corktree bark, 10 parts of sanchi, 10 parts of common public vine, 10 parts of camphor, 5 parts of borneol, 10 parts of catechu, 10 parts of white drug seed, 10 parts of airpotato yam, 10 parts of notopterygium root, 10 parts of divaricate saposhnikovia root, 10 parts of drynaria rhizome, 10 parts of radix clematis, 100 parts of guangdaline, 500 parts of refined sesame oil.
4. The plaster for treating osteoarthritis as claimed in claim 1, wherein the plaster is prepared from the following raw materials in parts by weight:
20 parts of raw radix aconiti, 20 parts of raw kusnezoff monkshood root, 20 parts of semen pini koraiensis, 20 parts of white mustard seed, 20 parts of pollen typhae, 20 parts of raw rhubarb, 20 parts of large-leaf gentian root, 20 parts of frankincense, 20 parts of myrrh, 20 parts of safflower, 20 parts of stiff silkworm, 20 parts of arisaema tuber, 20 parts of Japanese ampelopsis root, 20 parts of ground beetle, 20 parts of earthworm, 20 parts of manchurian wildginger, 20 parts of dipsacus root, 20 parts of giant knotweed rhizome, 20 parts of scorpion, 20 parts of szechuan lovage rhizome, 20 parts of dragon's blood resin, 20 parts of amur corktree bark, 20 parts of sanchi, 20 parts of common public vine, 20 parts of camphor, 15 parts of borneol, 20 parts of catechu, 20 parts of white drug seed, 20 parts of airpotato yam, 20 parts of notopterygium root, 20 parts of divaricate saposhnikovia root, 20 parts of drynaria rhizome, 20 parts of radix clematis, 200 parts of minium, 700 parts of refined sesame oil.
5. A plaster for the treatment of osteoarthritis according to any one of claims 1-4, further comprising pharmaceutically acceptable pharmaceutical excipients.
6. A method for preparing a plaster for treating osteoarthritis as claimed in any one of claims 1 to 4, characterized by comprising the steps of:
1) Weighing the raw materials in parts by weight for later use;
2) Pulverizing pollen Typhae, olibanum, myrrha, radix Ampelopsis, eupolyphaga Seu Steleophaga, scorpio, sanguis Draxonis, notoginseng radix, camphora, borneolum Syntheticum, catechu, radix Stephaniae Cepharanthae, and rhizoma Dioscoreae Bulbiferae respectively, grinding into fine powder, sieving, mixing, and making into medicinal powder;
3) Mixing radix Aconiti, radix Aconiti Kusnezoffii, semen Pittospori Glabrati, semen Sinapis Albae, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, carthami flos, bombyx Batryticatus, rhizoma arisaematis, lumbricus, herba asari, radix Dipsaci, rhizoma Polygoni Cuspidati, rhizoma Ligustici Chuanxiong, cortex Phellodendri, caulis Erycibes, notopterygii rhizoma, radix Saposhnikoviae, rhizoma Drynariae, radix Clematidis, soaking in refined sesame oil for 7-10 days, pouring into a pot, frying with slow fire to golden yellow, taking out residues, retaining medicinal oil, adding Plumbum Preparatium, stirring, decocting until white smoke is generated, dripping water to form beads, finally turning off fire, air drying to warm, adding the powder obtained in step 2), and decocting to obtain paste;
4) And (3) carrying out hot melting on the ointment in the step (3), and uniformly spreading the ointment on the cut kraft paper, wherein each patch is 30-35g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310159373.2A CN116327852A (en) | 2023-02-23 | 2023-02-23 | Plaster for treating osteoarthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310159373.2A CN116327852A (en) | 2023-02-23 | 2023-02-23 | Plaster for treating osteoarthritis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116327852A true CN116327852A (en) | 2023-06-27 |
Family
ID=86893906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310159373.2A Pending CN116327852A (en) | 2023-02-23 | 2023-02-23 | Plaster for treating osteoarthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116327852A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010561A (en) * | 2018-10-10 | 2018-12-18 | 孙斌 | A kind of plaster and preparation method thereof |
-
2023
- 2023-02-23 CN CN202310159373.2A patent/CN116327852A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010561A (en) * | 2018-10-10 | 2018-12-18 | 孙斌 | A kind of plaster and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115837065B (en) | Traditional Chinese medicine composition and application thereof | |
| CN114209764B (en) | Pharmaceutical composition, preparation and application for treating fracture | |
| CN103142707B (en) | Traditional Chinese medicine paste or treating chronic soft tissue injury and preparation method thereof | |
| CN113144062B (en) | Pharmaceutical composition for treating rheumatoid arthritis and preparation method and application thereof | |
| CN114652674A (en) | Blood circulation promoting and pain relieving ointment and preparation method thereof | |
| CN116327852A (en) | Plaster for treating osteoarthritis and preparation method thereof | |
| CN103705632A (en) | Application of mammary aggregation dispersing tablets in preparation of medicines for treating penis hardening disease | |
| CN1772245A (en) | Snake medicinal wine for health care massage and its application | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN110664890A (en) | Traumatic injury ointment | |
| CN1270741C (en) | Psoralea pill | |
| CN115814040B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN104873902B (en) | A kind of traditional Chinese medicine plaster for treating wound, osteopathy | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN115624582B (en) | New prescription for treating knee pain and preparation method and application thereof | |
| CN113813325B (en) | Erwu analgesic powder and preparation method thereof | |
| CN115025187B (en) | Traditional Chinese medicine composition for treating lumbago, acupoint plaster and preparation method and application thereof | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN115944680B (en) | Traditional Chinese medicine detumescence emplastrum for treating orthopedics postoperative red swelling and ecchymosis and preparation method thereof | |
| CN115154504B (en) | Traditional Chinese medicine composition for treating yang deficiency and blood stasis type gonarthritis as well as preparation method and application thereof | |
| CN115177690B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN1562117A (en) | Chinese medicinal preparation for quick bone fracture setting | |
| CN115137801B (en) | Traditional Chinese medicine composition for treating cervical spondylosis, acupoint plaster, and preparation method and application thereof | |
| CN107158188A (en) | A kind of Chinese medicine preparation for promoting fractures and bone injuries to heal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |